High-Tc Susceptometer to Monitor Transfusional Iron Overload
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01241357|
Recruitment Status : Completed
First Posted : November 16, 2010
Last Update Posted : September 21, 2016
|Condition or disease||Intervention/treatment|
|Transfusional Iron Overload Thalassemia Major Sickle Cell Disease Myelodysplastic Syndromes Aplastic Anemia||Device: Hepatic biomagnetic susceptibility measurement|
|Study Type :||Observational|
|Actual Enrollment :||99 participants|
|Official Title:||High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device)|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||May 2016|
This study has a single arm and no intervention.
Device: Hepatic biomagnetic susceptibility measurement
Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
- Hepatic non-heme iron concentration determined by biomagnetic susceptometry [ Time Frame: 2 years ]The primary study analysis will be a comparison of the results of measurements of the hepatic storage iron concentration by biomagnetic susceptometry with the results of biochemical analysis of the storage iron concentration in liver tissue.
- Serum ferritin concentration [ Time Frame: 2 years ]A secondary study analysis will be a comparison of the results of measurements of the hepatic storage iron concentration by biomagnetic susceptometry with the results of measurements of the serum ferritin concentration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01241357
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Gary M. Brittenham, M.D.||Columbia University|